Health-related quality of life in Spanish breast cancer patients: a systematic review

María Concepción Delgado-Sanz1†, María José García-Mendizábal1,2†, Marina Pollán1,2, Maria João Forjaz3,4, Gonzalo López-Abente1,2, Nuria Aragonés1,2, Beatriz Pérez-Gómez1,2*

Abstract

**Background:** Breast cancer is one of the oncological diseases in which health-related quality of life (HRQL) has been most studied. This is mainly due to its high incidence and survival. This paper seeks to: review published research into HRQL among women with breast cancer in Spain; analyse the characteristics of these studies; and describe the instruments used and main results reported.

**Methods:** The databases consulted were MEDLINE, EMBASE, PsycINFO, Dialnet, IBECS, CUIDEN, ISOC and LILACS. The inclusion criteria required studies to: 1) include Spanish patients, and a breakdown of results where other types of tumours and/or women from other countries were also included; and, 2) furnish original data and measure HRQL using a purpose-designed questionnaire. The methodological quality of studies was assessed.

**Results:** Spain ranked midway in the European Union in terms of the number of studies conducted on the HRQL of breast cancer patients. Of the total of 133 papers published from 1993 to 2009, 25 met the inclusion criteria. Among them, only 12 were considered as having good or excellent quality. A total of 2236 women participated in the studies analysed. In descending order of frequency, the questionnaires used were the EORTC, FACT-B, QL-CA-Afex, SF-12, FLIC, RSCL and CCV. Five papers focused on validation or adaptation of questionnaires. Most papers examined HRQL in terms of type of treatment. Few differences were detected by type of chemotherapy, with the single exception of worse results among younger women treated with radiotherapy. In the short term, better results were reported for all HRQL components by women undergoing conservative rather than radical surgery. Presence of lymphedema was associated with worse HRQL. Three studies assessed differences in HRQL by patients’ psychological traits. Psychosocial disorder and level of depression and anxiety, regardless of treatment or disease stage, worsened HRQL. In addition, there was a positive effect among patients who reported having a “fighting spirit” and using “denial” as a defence mechanism. One study found that breast cancer patients scored worse than did healthy women on almost all SF-12 scales.

**Conclusion:** Research into health-related quality of life of breast-cancer patients is a little developed field in Spain.

**Background**

Taking both sexes into account, breast cancer is the most frequent tumour in Europe [1]. It is one of the oncological diseases for which it has become almost standard practice to include the study of the disease’s impact on health-related quality of life (HRQL) among the priority research goals [2], particularly in the English-speaking world [3].

HRQL can be defined as self-perceived aspects of well-being that are related to or affected by the presence of a disease or treatment [4]. As a multidimensional construct, it includes perceptions, both positive and negative, of several dimensions such as physical, emotional, social and cognitive functioning. It also includes the negative aspects of somatisation disorder and symptoms caused by a disease and/or its treatment [5]. Studies undertaken in different settings or in different countries might display slight divergences, as HRQL is also modulated by cultural and care patterns.
In the case of breast cancer, disease severity and type of treatment (surgery, radiotherapy, chemotherapy, or a combination of all three) have a clear influence on the patient’s subjective perception of the disease. Their effects on HRQL are also modulated by personality traits, personal resources, availability and perception of social and family support [6], as well as by the strong cultural association between the breast and women’s self-esteem and sexuality [7].

A recent review of definitions and conceptual models of HRQL applied to oncological patients classifies HRQL-measurement instruments validated for use in cancer patients into two categories. Questionnaires specifically designed for the disease explore the repercussions of the most usual symptoms and side-effects, and are appropriate for comparing treatments or changes in patients. The general instruments are applicable to any population, and are better suited to studies that seek to ascertain the disease’s repercussion on HRQL, taking the general population as reference [8]. Among the former, the most used in Europe for breast cancer are the European Organization for Research and Treatment of Cancer Core Cancer Quality Life Questionnaire (EORTC QLQ-C30) and its breast-cancer-specific module (EORTC-BR23). Among the latter, the Medical Outcomes Survey Short-Form General Health Survey (SF-36) is the most widely used [9].

Although breast cancer incidence is lower in Spain than in other European countries, the number of new cases, which was estimated at 22985 women in 2006 [1], has shown a clearly rising trend from the 1980s until the year 2000 [10]. Spanish women are estimated to have a 6%-9% lifetime risk of developing this tumour [11]. Screening programmes, along with diagnostic and therapeutic advances, have led to a steady decline in mortality rates since the early 1990s, [12,13], and the estimated survival at five years of diagnosis currently stands at 86% [14]. Hence, as the number of women living with this tumour in Spain progressively rises, the study of HRQL should become a research topic of increasing relevance. Studies on Spanish breast cancer patients might reflect specificities that could help improve and focus care in such women. To this end, we performed a systematic review of HRQL research targeting breast cancer patients in Spain, analysing the studies published and instruments used, and summarizing the main results reported.

**Methods**

**Search strategy**

The databases consulted were MEDLINE via PubMed, EMBASE, PsycINFO, Dialnet, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), CUIDEN, ISOC and Literatura Latinoamericana y del Caribe en Ciencias de la Salud (LILACS). The information found was supplemented by manual searches based on the references cited in the papers initially identified. The MeSH terms used for the search were as follows: “Quality of life” AND “Breast Neoplasm” AND “Spain” in PubMed, EMBASE and PsycINFO, with “Breast Cancer” also being used as a key word; “Quality of life” AND “Breast cancer” in Dialnet; “quality” AND “life” AND “cancer” AND “breast” in IBECS; “quality of life” and “breast cancer” and “Spain” as the key words in CUIDEN; “cancer” AND “breast” AND “quality” AND “life” in ISOC; and lastly, the terms “Neoplasms of breast”, “Spain” and “Quality of life” in LILACS.

The search was conducted until August 2009, without restrictions of language or year of publication. In addition, the same search strategy used in the two main databases (PubMed and PsycINFO) was then applied to each European Union (EU) country. This enabled us to obtain an idea of Spain’s relative interest in HRQL research in breast cancer patients within a more international context. The systematic search and review processes were conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement criteria.

**Inclusion and exclusion criteria**

Detailed analyses were solely performed in the case of papers reporting Spanish studies. Several inclusion criteria were established. In the case of original papers, studies were required: 1) to include Spanish patients with breast cancer; and 2) to furnish original data and measure HRQL as an independent construct, using a specific questionnaire. We excluded any study in which the results were not broken down by country of origin when women from different countries took part, or by type of tumour when patients with different tumour sites were included.

**Data-extraction**

Two researchers participated independently and sequentially in the search for and selection of papers. The complete text of the most relevant papers was obtained and the papers were checked for inclusion criteria. Data on the authors’ names, year of publication, journal, study title, questionnaire used to measure HRQL, disease stage, type of treatment, sample size, and conclusions about HRQL were collected using a pre-established structured form set out in the review protocol. The information extracted by the two reviewers was then compared and, in case of disagreement, the opinion of a third reviewer was accepted as the criterion for the paper being included or not.

**Quality assessment**

The methodological quality of each of the selected papers was assessed through two checklists based on the
ones used in two systematic reviews[15,16]. Validation studies were assessed using the following criteria: reliability, type of criterion measure, and validity. Each criterion was rated as high, moderate, or low. These three ratings were condensed into a five-level overall judgment (excellent, good, moderate, fair, or poor) using the same decision rules as Vodermaier et al.[16].

The remaining papers were assessed according to the adapted list of Mols and Denollet’s [15] criteria, which included the following items: 1) a validated questionnaire is used; 2) a description is included of at least the stage and type of treatment; 3) inclusion and/or exclusion criteria are described; 4) a information is given about the degree of the sample selection; 5) a participation rates for patient groups are described and are more than 75%; 6) study size of at least 100 participants; 7) the process of data collection is described; 8) the results are compared between two groups or more; and 9) statistical proof of the findings is reported. Each item received a score of one or zero depending on whether or not it fulfilled the criterion. According to the score obtained, studies were arbitrarily considered as: excellent (a score of 8-9); good (6-7); moderate (4-5); fair (2-3); and poor (0-1).

Results

Figure 1 graphically depicts the results of the search made for each EU country in PubMed and PsycINFO. While the United Kingdom and Germany were the two countries with most references in both databases, Eastern European countries generally had very few studies. Spain occupied a middle-ranking position according to PubMed, although it was one of the countries with most references in PsycINFO.

Figure 2 shows the flowchart of the systematic review process followed in the case of Spanish papers. The initial search located a total of 133 publications, 82% in Dialnet, PsycINFO, PubMed and EMBASE. After duplicated references had been discarded, 45 papers were reviewed, with 25 papers that fulfilled the inclusion criteria being identified. The studies selected are shown in Table 1. All were published from 1993 to 2009, with the majority (80%) being published in home-based Spanish-language journals and only five in international English-language journals. A total of 2236 women participated in these studies, with sample sizes ranging from 10 to 583 participants (median, 98). The table included as Additional File 1 lists the basic characteristics of the studies identified in the review and provides a summary of their principal results.

Study objectives

The goal of five studies was the validation or adaptation of questionnaires [17-21]. Another fourteen papers focused on studying the repercussions of different therapies on patients’ HRQL. The most common objective (seven studies) was assessing the possible beneficial effect of psychotherapy and related factors [22-28]. Insofar as medical treatments were concerned, the studies compared the effects on HRQL of different types of chemotherapy [29,30], radiotherapy [31] or surgery [32-34]. Similarly, one pilot study examined the efficacy of cardiovascular training on HRQL [35]. In addition, two papers investigated how HRQL might be influenced by lymphedema [36,37]. Two research studies considered variability in patients’ HRQL according to personality traits [38,39]. Another analysed the influence of HRQL...
on body image and self-esteem [40]. Lastly, one study addressed the overall repercussions of the disease, comparing the HRQL of women with breast cancer with that of healthy women [41].

### Questionnaires

Seven HRQL instruments were identified. The EORTC questionnaires were the most used, in both the original form QLQ-C30 and the Spanish version, with a specific module for breast cancer, i.e., the QLQ-BR23 [19-21,25,31,33-36], and the version adapted for breast cancer by Toledo in 1993 [17,23,28,29,32,38-40]. Some of the retrieved studies made express reference to the construction and validation of the breast-specific module [19]. The QLQ-C30 [42] is a self-administered questionnaire specifically for cancer patients, drawn up and designed to be used in national and international studies. It is relatively short, with a mean completion time of 10 minutes. It has a multidimensional structure, with multi-item scales that cover four basic HRQL dimensions: disease symptoms and toxicity; physical functioning and role-physical; psychological dimension; and social dimension. It uses Likert-type scales, and all dimensions are summarized in a final score, ranging from 0 to 100. In Spain, this questionnaire has

| Author(s) [Ref.] | Year | Objective | HRQL assessment |
|------------------|------|-----------|-----------------|
| Toledo et al. [17] | 1993 | Adaptation of EORTC questionnaire | EORTC (adapted) |
| Font [18] | 1994 | Validation of questionnaire | QL-CA-Afex |
| Ferrero et al. [38] | 1994 | To explore the relationship between mental adaptation to cancer and QL | EORTC (adapted) |
| Ferrero et al. [39] | 1995 | Time trend in HRQL and its association with coping with the disease | EORTC (adapted) |
| Blasco et al. [29] | 1995 | To ascertain the effect on HRQL of autologous treatment with support of peripheral hematopoietic cells | EORTC (adapted) QL-CA-Afex |
| Cagigal Rodríguez et al. [30] | 1995 | Comparison of the effect of 3 different types of chemotherapy on HRQL | RSCL FLIC |
| Sprangers et al. [19] | 1996 | Validation of questionnaire | QLQ-BR23 |
| Toledo et al. [32] | 1996 | To assess global QL after surgery and before adjuvant treatments | EORTC (adapted) |
| Ruiz et al. [22] | 1998 | To establish a psychological profile for interventions targeted at improving psychosocial adjustment | CCV |
| Sebastián et al. [23] | 1999 | To assess the efficacy of a psychological group intervention program | EORTC (adapted) |
| Condón et al. [36] | 2000 | To ascertain the impact of lymphedema on QL | QLQ-C30 QLQ-BR23 |
| Arraras et al. [20] | 2000 | Psychometric study of the QLQ-C30 questionnaire (version 2.0) | QLQ-C30 |
| Arraras et al. [21] | 2001 | Validation of the QLQ-BR23 questionnaire with Spanish sample | QLQ-B23 |
| Arraras et al. [33] | 2001 | To assess QL during treatment | QLQ-C30 QLQ-B23 |
| Arraras et al. [34] | 2003 | To assess QL after a long follow-up period, and study differences in QL by disease stage, surgery, and adjuvant treatment | QLQ-C30 QLQ-BR23 |
| Font et al. [24] | 2004 | To show the efficacy of a psychological group intervention, by analyzing variations in HRQL before and after therapy | QLQ-C30 QLQ-BR23 |
| Cervera et al. [41] | 2005 | To study the impact of diagnosis of breast cancer on patients’ psychological (psychopathology and QL) and conjugal adjustment | SF-12 |
| Manos et al. [40] | 2005 | To analyze the influence of some variables (socio-demographic, type of surgery, social support, and QL) on body image and self-esteem | EORTC (adapted) |
| Sánchez et al. [25] | 2005 | To analyze variables related with withdrawal from a psychological group intervention program | QLQ-C30 |
| Herrero et al. [33] | 2006 | To evaluate the efficacy of a cardiovascular training and resistance program vis-à-vis functional capacity and QL | QLQ-C30 |
| Yélamos et al. [37] | 2007 | To compare the QL of women operated on breast cancer with and without lymphedema | FACT-B +4 |
| Páez et al. [26] | 2007 | To compare acceptance and commitment therapy as against cognitive-behavioural therapy. | FACT-B |
| Bellver [27] | 2007 | To assess the efficacy of two types of group therapy on the emotional state and QL of women with breast cancer, on termination of adjuvant treatments. | FACT-B |
| Arraras et al. [31] | 2008 | To make a prospective assessment of the QL of elderly patients who initiated treatment with radiotherapy, and compare it with that of a sample of younger patients | FACT-B |
| Manos [28] | 2009 | To assess a psychosocial intervention program | EORTC (adapted) |

EORTC: European Organization for Research and Treatment of Cancer; HRQL: health-related quality of life; QL: quality of life.
been the subject of validation studies, using samples of patients with cancer of the breast, lung, and head and neck [20,43].

The breast-cancer-specific QLQ-BR23 questionnaire [19] assesses areas related to the various treatment modalities (surgery, radiotherapy, chemotherapy, and hormonal therapy). It also assesses other specific aspects of HRQL in breast cancer patients, such as body image or sexuality. The questionnaire consists of two parts: level of functioning and symptoms, each with several individual scales and items. One of the studies included here [17] reported the validation of this questionnaire with a Spanish population. While Toledo’s questionnaire [17] can be considered as having good construct validity and internal consistency, neither the version of the EORTC questionnaire on which it was based, nor the process of translation, is clearly specified.

Three studies published in 2007 [26,27,37] used the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument, a questionnaire made up of 36 items [44] and designed to measure the HRQL of breast cancer patients in different dimensions. Like the EORTC questionnaires, the FACT-B comprises a general instrument for cancer, FACT-G, complemented by a subscale containing items specific to breast cancer. The items are grouped into five subscales and are answered through five-point response scales. The FACT-B displays good reliability, validity and sensitivity to change [45].

A third instrument for measuring the HRQL in breast cancer patients was the QL-CA-Afex, created by Antóni Font in 1988 and used by the author in two studies, one of which was a validation study [18,24]. The QL-CA-Afex comprises 27 items (visual analogue scales) scored from 0 to 100 and grouped into the following 4 subscales: symptoms; autonomy; familial and social difficulties; and psychological difficulties. Although it is an instrument for chronic diseases, it has been validated with breast cancer patients. One of the studies, with a sample size of only 10 patients, showed a low correlation coefficient with the EORTC instruments [29].

Only one study [30] used the Functional Living Index Cancer (FLIC), a general HRQL questionnaire for cancer patients. It evaluates five HRQL dimensions: physical wellbeing; emotional status; sociability; family situation; and side-effects of treatment [46]. The FLIC displays good content validity and is easy to administer. We failed to find a version of this questionnaire adapted to and validated for the Spanish population. This same paper [31] also included the version of the Rotterdam Symptom Checklist (RSCL) geared to the breast cancer population. The applied version has 38 items using a 4-point Likert-type response scale. It assesses functional level, symptoms, psychological functioning and sexual relations, and includes a global HRQL score. Like the previous questionnaire, the RSCL version used was neither adapted to nor validated for the Spanish population, since the cultural adaptation dates from 1998 [47] and the study in question was conducted in 1995.

Lastly, two studies used generic HRQL instruments. One [41] used the SF-12, a short version of the SF-36 for the general population. It is a questionnaire which has been translated into and validated in Spanish. The SF-12 is made up of 8 subscales (physical health, physical functioning, bodily pain, general health, vitality, social functioning, emotional functioning, and mental health), summarized into two global measures: physical and mental. Another study [22] used the Quality of Life Questionnaire (Cuestionario de Calidad de Vida, CCV), originally developed in Spanish and formally validated in Spain [48]. It comprises 39 items grouped into 4 subscales: general satisfaction, social support, physical/psychological wellbeing, and absence of work overload/leisure time.

HRQL results for women with breast cancer

Comparison between patients and healthy women

The only study [41] to address this objective reported that women with breast cancer displayed greater deterioration in their HRQL, scoring worse on almost all SF-12 scales.

Treatments and pathology associated with the disease

With respect to the studies about the influence of treatments on HRQL, one [30] reported few differences in HRQL among the study groups receiving different types of chemotherapy. As regards the influence of radiotherapy on the HRQL of persons aged 65 years and over, one study [31] observed no significant differences prior to and at 6 months of treatment.

Insofar as psychotherapy was concerned, one study [24] found better HRQL scores in groups that underwent some type of psychological group therapy than in those that received no treatment. Another study [28] observed less depression and psychological distress among those treated. However, no relationship was found between withdrawal from group psychotherapy and HRQL [25,27]. With respect to the type of psychotherapy, one paper [26] concluded that acceptance and commitment therapy yielded better HRQL results than the cognitive therapy which the control group received.

Studies which assessed the effect of surgery [31,34,41] reported that conservative surgery had fewer repercussions on HRQL than did radical surgery, and that HRQL was better for women with sentinel lymph node biopsy than aggressive axillary surgery. One pilot study [35] observed significant improvements in global quality of life and physical functioning in the group of women who had taken part in a cardiovascular training program.
versus the control group. The two studies on HRQL and lymphedema [36,37] both concluded that the presence of this disorder was associated with worse HRQL.

**Psychological traits**

The studies that assessed variations in HRQL according to patients’ psychological traits observed that psychosocial disorders worsened HRQL. In addition, the patients who best preserved their HRQL used coping strategies suited to the situation, maintained high self-referential outcome expectations, and had a certain subjective sensation of control over the disease and its effects [38]. Similarly, significant differences were observed in quality of life according to the level of depression and anxiety, regardless of treatment or disease stage [22]. One study observed a positive effect on HRQL among patients who reported having a “fighting spirit” and using “denial” as a defence mechanism, whilst “helpless/hopeless”, “fatalism” and “anxious preoccupation” were associated with worse HRQL [39].

**Methodological quality of the Studies**

The additional file provides the summary judgments for the predefined evaluation criteria. Three of the studies were considered to be of poor quality according to our checklist [17,19,21]. Only one paper was evaluated of a fair quality [29]. Nine were assessed of a moderate quality [18,22,26,30-32,34,38,40]. Of the remaining studies, eleven were of a good quality [20,23-25,27,28,33-37,39] and one paper was of an excellent quality [41].

**Discussion**

Our results indicate that research into the HRQL of breast cancer patients is a little developed field in Spain. Despite being one of the most populated countries in Western Europe, Spain ranks among those with the lowest number of studies addressing this issue. There appear to be two different publishing patterns among European researchers active in this field. In the majority of cases, papers are published in medical journals, and so PubMed is the bibliographic database with most information. In the case of Germany and The Netherlands, however, there are similar numbers of papers in PsycINFO and PubMed, probably reflecting a more multidisciplinary approach. This would also seem to apply to Spain. Almost half the studies included in this review were indexed in PsycINFO. Fewer papers were published from the medical side. Indeed, the leading medical bibliographic database, PubMed, contained only four of the studies included in this systematic review, all of which had been published in international journals [19,28,31,35].

In this systematic review, we found only 25 papers that met all inclusion criteria. Five of these, published between 1993 and 2001, reported validations or cultural adaptations of questionnaires. Most of the others examined HRQL by type of treatment, or analysed the influence of treatments and specific symptoms on HRQL. A different approach was shown by the three studies that assessed differences in HRQL by psychological traits. Lastly, one report compared the HRQL of patients with healthy women.

The total number of papers identified was low, despite the general recommendation to include HRQL as an outcome in clinical studies involving breast cancer patients [49], and the fact that HRQL questionnaires are routinely used in clinical research. This reflects the scant attention paid to the information afforded by these instruments. Excluding validation studies, the instruments most commonly used to measure quality of life were the EORTC questionnaires (EORTC QLQ-C30 and QLQ-B23) or modified versions of these (13 studies), with the FACT-B ranking second (3 studies). Aside from being instruments with adequate psychometric characteristics for measuring HRQL in cancer patients [19,42,45], they are also the most widely used in international breast cancer studies [3]. However, only the EORTC QLQ-C30 and QLQ-B23 have versions validated in Spanish [20,21,43].

Breast cancer is one of the neoplasms in which the treatment of choice, surgery, tends to be combined with other therapeutic strategies, such as chemo-, radio- or hormonal therapy. Yet, our results show that studies in Spain aimed at evaluating the effect of treatments on HRQL are clearly insufficient, and in the case of some therapies, non-existent. Surgical repercussions on HRQL are a relatively common issue in international studies [3]. This is because surgery is the initial treatment, at least in stages I, II and III, for most breast cancer patients [50]. Nevertheless, there is a notable lack of papers in Spain focused on the effect of surgery on HRQL. Indeed, this review was able to locate only four papers which made reference to this topic [31,32,34,41], and only one of these included the questionnaire scores [41]. This last-mentioned study compared conservative with radical surgery. It reported better results for the former treatment in all components of HRQL in the short term. In this particular instance, differences were not studied by age group, though these were reported in a paper from Canada [51]. Studies undertaken in other countries (Canada, Germany, and Japan) report contradictory results for these two surgical approaches in terms of differences in HRQL in the long term [51-53]. Only one of the Spanish studies considered axillary surgery [31]. While the authors reported that HRQL was better among sentinel lymph node biopsy patients than axillary emptying, they failed to furnish the specific results.

Insofar as radiotherapy was concerned, we found a single follow-up study [31], which observed no significant differences at 6 months of treatment, whether
overall or by age group. This reinforces the idea that age should not be the only factor considered when deciding about oncology treatments, as reported in a study from the United Kingdom [54].

The most common objective (seven studies) was to assess the possible beneficial effect of psychotherapy [22-28]. The improvements in HRQL associated with psychological therapies observed in Spanish studies are consistent with the results reported in two papers from the USA and Australia, respectively [55,56]. Two studies about the relationship between mental adaptation to cancer and HRQL observed differences according to patients’ age and coping strategies [38,39]. These results partially agree with those yielded by a study that targeted older women from the USA [57]. Nevertheless, it is difficult for our results to be compared with those of other studies, due to differences in study goals and in HRQL assessments involving psychological factors [58,59].

Only two studies addressed the negative impact of lymphedema on the HRQL of Spanish women with breast cancer [36,37], with findings consistent with two USA case-control studies [60,61]. In addition, our review revealed a lack of studies addressing the impact of other common symptoms, such as pain, fatigue or menopausal symptoms. This is in contrast with the attention paid to these items in international literature [3].

Just one study compared the HRQL of breast cancer patients with that of healthy women [41]. This is an area of great interest for quantifying the impact of breast cancer on our society in terms of HRQL. However, no longitudinal study was identified that was capable of evaluating trends in HRQL over time. In view of the low fatality rate of breast cancer patients at the present time, it would be of great value to have access to studies designed to assess the long-term repercussions of the disease on the lives of the women affected.

Some studies (e.g., such as those undertaken by the Breast Cancer Study Group (http://www.ibcsg.org/), in which a Spanish team participated [62], and the papers by Martín et al [63,64]), were excluded in spite of Spanish patients being included in the sample. This was due to failure to report the results with a breakdown by country. Similarly, no consideration was given to studies that pooled patients with different types of cancer but furnished no specific information about women with breast cancer [65-69]. Finally, we also excluded studies that failed to use HRQL-specific instruments [70] or reported no specific results for this construct [71].

The bibliographic search-and-screening phase showed us that the term HRQL has not been interpreted by some Spanish authors in line with the concept of the multidimensional construct to which it refers. According to the WHO, quality of life is, “an individual’s perception of his/her position in life in the context of the

The comprehensive search performed, which included international as well as national bibliographic databases, as well as the review process have been performed following PRISMA statement criteria. However, we could not perform a meta-analysis due to the small number of
studies found and to the heterogeneity of goals and results. Additionally, the exclusion of some international studies [62-64] due to the inclusion criteria adopted could be seen as a limitation of the review in its goal to reflect the research made in Spain on HRQL in Breast Cancer patients.

In brief, there is clearly insufficient information available on the HRQL of Spanish women with breast cancer. Since HRQL is one of the principal result indicators for improving the care of and evaluating new treatments for such patients, encouragement should be given to promoting research and publication in this field.

Additional material

Additional file 1: Studies on quality of life and breast cancer among Spanish women (1993-2009): basic characteristics and summary of principal results.

Abbreviations

CCV: Quality-of-life questionnaire (Cuestionario de Calidad de Vida); CUIDEN: Nursing database kept by the Index Foundation; EORTC: European Organization for Research and Treatment of Cancer; EORTC QLQ-BR23: European Organization for Research and Treatment of Cancer Quality Life Questionnaire Breast Cancer Specific Module; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Core Cancer Quality Life Questionnaire; FACT-B: Functional Assessment of Cancer Therapy-Breast; FLIC: Functional Living Index Cancer; HRQL: Health-related quality of life; IEBCS: Spanish Health Science Bibliographic Index (Índice Bibliográfico Español en Ciencias de la Salud); ISOC: Social sciences and humanities database kept by the Spanish Research Board (Consejo Superior de Investigaciones Científicas - CSIC); LILACS: Latin-American & Caribbean Health Science Literature (Literatura Latinoamericana y del Caribe en Ciencias de la Salud); RSCL: Rotterdam Symptom Checklist; SF-36 & SF-12: Medical Outcomes Survey Short-Form General Health Survey with 36 or 12 items.

Acknowledgements

M.I García-Mendizábal’s work was funded by the Carlos III Institute of Health (Instituto de Salud Carlos III - ISCIII) Grant EPY 05/0001. We would like to thank the Spanish Epidemiological Society (Sociedad Española de Epidemiología) for the Research Prize awarded to this study at the Society’s 26th Annual Scientific Meeting held in Gerona in October 2008.

Authors details

1Department of Cancer and Environmental Epidemiology, National Centre for Epidemiology, Carlos III Institute of Health, Avda. Monforte de Lemos 5, 28029 Madrid, Spain. 2Consortium for Biomedical Research in Epidemiology, Carlos III Institute of Health, Avda. Monforte de Lemos 5, 28029 Madrid, Spain. 3Consortium for Biomedical Research in Neurodegenerative Diseases (CIBER en Enfermedades Neurodegenerativas - CIBERNED).

Authors’ contributions

MP and BPG contributed to the conception and design of the review; MCDS and MIGA collected and analyzed the data and drafted the manuscript; MIF and BPG contributed to the analysis and interpretation of the data and to putting the finishing touches to the manuscript. NA, MIF, GLA, MP, and BPG conducted a critical review of the manuscript for important intellectual content. All authors had unrestricted access to all data examined and gave their approval to the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 25 May 2010 Accepted: 14 January 2011 Published: 14 January 2011

References

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2007. Ann Oncol 2007, 18:581-592.
2. Ganz PA, Goodwin PJ: Quality of life in breast cancer - what have we learned and where do we go from here? In Outcomes Assessment in Cancer. Measures, Methods, and Applications. 1 edition. Edited by: Lipshcimb J, Gotay CC, Snyder C. Cambridge: Cambridge University Press; 2005:93-125.
3. Montazeri A: Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008, 27:32.
4. Ebrahim S: Clinical and Public-Health Perspectives and Applications of Health-Related Quality-Of-Life Measurement. Soc Sci Med 1995, 41:1383-1394.
5. Osoba D: Lessons Learned from Measuring Health-Related Quality-Of-Life in Oncology. J Clin Oncol 1994, 12:608-616.
6. Die Trill M, Die Gayanes A: El cáncer de mama. En Psico-Oncología. Edited by: Die Trill M. Madrid: Aula de Estudios Sanitarios; 2003:165-184.
7. Rowland JH, Massie MJ: Breast Cancer. In Psico-Doncology. Edited by: Holland JC. New York: Oxford University Press; 1998:361-401.
8. Ferraris CE: Definitions and conceptual models of quality of life. In Outcomes Assessment in Cancer. Measures, Methods, and Applications. 1 edition. Edited by: Lipshcimb J, Gotay CC, Snyder C. Cambridge: Cambridge University Press; 2005:14-30.
9. Erickson P: Assessing health status and quality of life of cancer patients: the use of general instruments. In Outcomes Assessment in Cancer. Measures, Methods, and Applications. 1 edition. Edited by: Lipshcimb J, Gotay CC, Snyder C. Cambridge: Cambridge University Press; 2005:31-68.
10. Pollan M, Pastor-Barriuso R, Ardanaz E, Aragüelles M, Martos C, Galceran J, Sánchez-Perez MJ, Chirafaque MD, Larranaga N, Martínez-Cobo R, Tobalina MC, Vidal E, Marcos-Gragera R, Mateos A, Garau J, Rojas-Martín MD, Jimenez R, Torrella-Ramos A, Pusicha M, Perez de Rada ME, Gonzalez S, Rabanaque MJ, Borras J, Navarro C, Hernandez E, Izquierdo A, Lopez-Abente G, Martínez C: Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst 2009, 101:1584-1591.
11. Pollán M, García-Mendizábal MJ, Pérez-Gómez B, Aragónes N, López-Abente G: Lessons Learned from Measuring Health-Related Quality-off-Life in Oncology. J Clin Oncol 1994, 12:608-616.
12. Cabanes A, Vidal E, Perez-Gomez B, Aragones N, López-Abente G, Pollan M: Age-specific breast, uterine and ovarian cancer mortality trends in Spain: changes from 1980 to 2006. Cancer Epidemiol 2009, 33:169-175.
13. Cabanes A, Vidal E, Aragones N, Perez-Gomez B, Pollan M, Lopez V, Lopez-Abente G: Cancer mortality trends in Spain: 1980-2007. Ann Oncol 2010, 21:i14-i20.
14. Chirafaque MD, Salmerón D, Ardanaz E, Galceran J, Martínez R, Marcos-Gragera R, Sacristán A, Sánchez M, Mateos A, Torrella A, Capocaccia R, Navarro C: Cancer survival in Spain: estimate for nine major cancers. Ann Oncol 2010, 21:i21-i29.
15. Mols F, Denollet J: Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems. Health Qual Life Outcomes 2010, 8:9.
16. Vodermairer A, Linden W, Su C: Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 2009, 101:1464-1488.
17. Toledo M, Barreto MP, Pascual A, Ferrero J: Adaptación del cuestionario de calidad de vida de la E.O.R.T.C. para cáncer de mama. Rev Psicol Salud 1993, 3:29-45.
18. Font A: Cáncer y calidad de vida. Anu Psicol 1994, 61:41-50.
19. Sprangers MA, Grootveld M, Araris JL, Franklin J, Te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996, 14:2356-2368.
20. Arraras JL, Garidio E, Puja E, Marcos M, Tejedor M, Arias F: El Cuestionario de Calidad de Vida de la EORTC QLQ-C30 (Versión 2.0). Estudio psicométrico con pacientes con cáncer de mama. Clin Salud 2000, 11:329-349.
21. Arraras JI: El cuestionario de calidad de vida para cáncer de mama de la EORTC, QLQ-C30: Estudio psicométrico con una muestra española. Psicol Conduc 2001, 9:81-97.
22. Ruiz MA, Garde S, Asuncion N, Del Moral A: Intervención psicológica en pacientes con cáncer de mama. An Sis San Navarrot 1998-1998, 21:119-124.
23. Sebastián J, Bueno MJ, Mateos N, García P: Evaluación de un programa de intervención sobre cáncer de mama. Bol Psicol 1999, 6:53-73.
24. Font A, Rodríguez E: Eficacia de la terapia de grupo en cáncer de mama: Variaciones de la calidad de vida. Psicoconocco 2004, 1:67-88.
25. Sánchez N, Torres A, Camprubí N, Vidal A, Salamero M: Factores predictores de abandono de la intervención psicológica grupal en una muestra de pacientes con cáncer de mama. Psicoconocco 2005, 2:21-32.
26. Páez MB, Luciano C, Gutiérrez O: Tratamiento psicológico para el afrontamiento del cáncer de mama. Estudio comparativo entre estrategias de aceptación y de control cognitivo. Psicoconocco 2007, 4:75-95.
27. Belvelt E: Eficacia de la terapia grupal en la calidad de vida y el estado emocional en mujeres con cáncer de mama. Psicoconocco 2007, 4:133-142.
28. Manos D, Sebastian J, Mateos N, Bueno MJ: Results of a multi-component psychosocial intervention programme for women with early-stage breast cancer in Spain: quality of life and mental adjustment. Eur J Cancer Care (Engl) 2009, 18:295-305.
29. Blasco T, Rodríguez E: Calidad de vida y bienestar en pacientes de cáncer que reciben quimioterapia a altas dosis: Un estudio preliminar. Clin Salud 1995, 6:313-340.
30. Cagigal-Rodriguez JA, Velasco Sánchez MDM: Valoración subjetiva de la calidad de vida en pacientes con cáncer de mama metastásico durante el tratamiento con quimioterapia. Clin Salud 1995, 6:65-92.
31. Arraras JI, Manterola A, Domínguez MA, Arias F, Villafañe E, Romero P, Martínez E, Illarramendi JJ, Salgado E: Impact of radiotherapy on the quality of life of elderly patients with localized breast cancer. A prospective study. Clin Transl Oncol 2006, 8:498-504.
32. Toledo M: Cirugía del cáncer de mama y valoración de la calidad de vida global. Rev Psicol Univ Tarracon 1996, 18:17-37.
33. Arraras JI, Illarramendi JJ, Tejedor M: Quality of Life in Spanish breast cancer patients assessed with the EORTC questionnaires. Rev Oncol 2001, 3:100-106.
34. Arraras JI, Illarramendi JJ, Tejedor M: Quality of Life in Spanish breast cancer patients assessed with the EORTC questionnaires. Rev Oncol 2001, 3:73-82.
35. Yélamos C, Montesinos F, Eguino A, Fernández B, González A, García M, Delgado-Sanz J: Impact of radiotherapy on the quality of life in breast cancer patients: the Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
36. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Coleleigh M, Shimamoto: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997, 15:974-986.
37. Schipper H, Clinical J, McMurray A, Levitt M: Measuring the quality of life of cancer patients; the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984, 2472-483.
38. Agra Y, Badia X: Spanish version of the Rotterdam Symptom Check List: cross-cultural adaptation and preliminary validity in a sample of terminal cancer patients. Psychocoenologia 1998, 7:229-239.
39. Ruiz M: Design and validation of the “Quality of Life Questionnaire” (Cuestionario de Calidad de Vida, CCV, Eur J Psychol Assess 1993, 9:19-32.
40. Perry S, Kowalski T, Chang C: Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007, 5:24.
41. Martín M, Mahilio E, Llombart-Cussac A, Lluch A, Muniraz B, Pastor M, Alba E, Ruiz A, Anton A, Bermejo E: The “El Alamo” project (1999-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol 2006, 8:508-518.
42. Dorval M, Maunsell E, Deschenes L, Brisson J: Type of mastectomy and quality of life for long term breast carcinoma survivors. Cancer 1998, 83:2130-2138.
43. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D: Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast 2004, 10:223-231.
44. Shimozuma K, Ganz PA, Petersen L, Hejji K: Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery. Breast Cancer Res Treat 1999, 56:45-57.
45. Hopwood P, Haviland J, Mills J, Sumo C, Bliss M: The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial), Breast 2007, 16:241-251.
46. Menezes KD, McNees P, Loerzel WW, Su X, Zhang Y, Hassey LA: Transition from treatment to survivorship: effects of a psychoeducational Intervention on quality of life in breast cancer survivors. Oncol Nurs Forum 2007, 34:1007-1016.
47. Gordon LG, Battistutta D, Southam P, Tweeddale M, Newman B: The impact of rehabilitation support services on health-related quality of life for women with breast cancer. Breast Cancer Res Treat 2005, 93:217-226.
48. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Stillman RA: Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003, 21:4027-4033.
49. Longman AJ, Braden CJ, Mishel MH: Side-effects burden, psychological adjustment, and quality of life in women with breast cancer: pattern of association over time. Oncol Nurs Forum 1999, 26:909-915.
50. Badger TA, Braden CJ, Mishel MH, Longman A: Depression burden, psychological adjustment, and quality of life in women with breast cancer: patterns over time. Res Nurs Health 2004, 27:19-28.
51. Velanovich V, Szmukwski W: Quality of Life of breast cancer patients with lymphedema. Am J Surg 1999, 177:184-187.
52. Ridner SH: Quality of life and a symptom cluster associated with breast cancer treatment-related lymphedema. Support Care Cancer 2005, 13:904-911.
53. Gelber RD, Goldhirsh A, Cavalli F: Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Ann Intern Med 1991, 115:621-628.
54. Martin M, Penkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, At Tivege T, Chap L, Juhoes A, Gneuhr B, Howell A, Forand M, Haitmansworth J, Coleman R, Vinholes J, Molpado M, Penter T, Tang SC, Colwell B, Prady C, Provencier L, Walde D, Rodriguez-Lecuire A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Muravsky M, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
55. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adolver E, Rodriguez-Lescure A, Grosse C, Alba I, Fernandez-Chacon C, Roset M, Antón A, Isla D,
del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006, 17:1205-1212.

65. Blasco T, Inglés N: Calidad de vida y adaptación a la enfermedad en pacientes de cáncer durante el tratamiento de quimioterapia. Anu Psicol 1997, 72:81-90.

66. Padierna C, Fernández C, Amigo I, Gracia JM, Fernández R, Peláez I, Pérez M: Estudio longitudinal de los parámetros de calidad de vida en pacientes oncológicos. Psicooncología 2004, 1:191-204.

67. Terol MC, López-Roig S, Rodríguez-Marín J, Pastor MA, Mora M, Martín-Aragón M, Leyda-Menéndez JL, Neipp MC, Lizón J: Diferencias en la calidad de vida: Un estudio longitudinal de pacientes de cáncer recibiendo tratamiento de quimioterapia. An Psicol 2000, 16:111-122.

68. Leon-Pizarro C, Gich I, Barthe E, Rovira A, Fanús B, Casas F, Vergé E, Biete A, Craven-Bartle J, Sierra J, Arcusa A: A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psychooncology 2007, 16:971-979.

69. Espantoso R, Fernández C, Padierna C, Amigo I, Villona E, Gracia JM, Fernández R, Peláez I: Calidad de vida en pacientes oncológicos un año después de finalizado el tratamiento. Psicooncología 2007, 4:43-57.

70. García Lumbrañas S, Blasco T: Características de la sexualidad en mujeres con cáncer de mama. Psicooncología 2008, 5:155-170.

71. Bárez M, Blasco T, Fernández-Castro J, Wladrich C: Perceived control and psychological distress in women with breast cancer: a longitudinal study. J Behav Med 2009, 32:187-196.

72. Schwartzmann L: Calidad de vida relacionada con la salud: Aspectos conceptuales. Cienc Enferm 2003, 9:9-21.

73. Mianyo MCS, Hartz ZMA, Buss PM: Qualidade de vida e saúde: um debate necessário. Cien Saude Colet 2000, 5:7-18.

74. Forjaz MJ, Guarnaccia CA: A comparison of Portuguese and American patients with hematological malignancies: a cross-cultural survey of health-related quality of life. Psychooncology 2001, 10:251-258.

doi:10.1186/1477-7525-9-3

Cite this article as: Delgado-Sanz et al.: Health-related quality of life in Spanish breast cancer patients: a systematic review. Health and Quality of Life Outcomes 2011 9:3

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit